866-997-4948(US-Canada Toll Free)

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014

Published By :

Global Markets Direct

Published Date : Sep 2014

Category :

Head and Neck Cancer

No. of Pages : 259 Pages

Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014

Summary

Global Markets Directs, Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014, provides an overview of the Head And Neck Cancer Squamous Cell Carcinomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer Squamous Cell Carcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Head And Neck Cancer Squamous Cell Carcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Head And Neck Cancer Squamous Cell Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Head And Neck Cancer Squamous Cell Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer Squamous Cell Carcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Head And Neck Cancer Squamous Cell Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Head And Neck Cancer Squamous Cell Carcinoma Overview 9
Therapeutics Development 10
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Overview 10
Pipeline Products for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis 11
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Development by Companies 12
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 16
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Head And Neck Cancer Squamous Cell Carcinoma - Products under Development by Companies 21
Head And Neck Cancer Squamous Cell Carcinoma - Products under Investigation by Universities/Institutes 24
Head And Neck Cancer Squamous Cell Carcinoma - Companies Involved in Therapeutics Development 25
Bristol-Myers Squibb Company 25
Boehringer Ingelheim GmbH 26
F. Hoffmann-La Roche Ltd. 27
Shionogi & Co., Ltd. 28
Amgen Inc. 29
Eli Lilly and Company 30
GlaxoSmithKline plc 31
Celltrion, Inc. 32
Novartis AG 33
Eisai Co., Ltd. 34
ImmunoGen, Inc. 35
Santaris Pharma A/S 36
CEL-SCI Corporation 37
OXiGENE, Inc. 38
Takara Bio Inc. 39
Panacea Biotec Limited 40
PCI Biotech AS 41
Nanobiotix 42
Acceleron Pharma, Inc. 43
Virttu Biologics Limited 44
Ascenta Therapeutics, Inc. 45
Onconova Therapeutics, Inc. 46
Genexine, Inc. 47
Viventia Biotechnologies Inc. 48
Oncovir, Inc. 49
Gliknik, Inc. 50
Karyopharm Therapeutics, Inc. 51
Agonox 52
Tolero Pharmaceuticals, Inc. 53
AlphaMab Co., Ltd 54
SillaJen Co. Ltd. 55
Mirati Therapeutics Inc. 56
Head And Neck Cancer Squamous Cell Carcinoma - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Target 59
Assessment by Mechanism of Action 64
Assessment by Route of Administration 69
Assessment by Molecule Type 71
Drug Profiles 74
cetuximab - Drug Profile 74
Leukocyte Interleukin - Drug Profile 81
afatinib - Drug Profile 84
nimotuzumab - Drug Profile 87
nimorazole - Drug Profile 90
dalantercept - Drug Profile 92
SPC-2968 - Drug Profile 94
pemetrexed disodium - Drug Profile 96
everolimus - Drug Profile 102
rigosertib sodium - Drug Profile 106
oportuzumab monatox - Drug Profile 110
buparlisib hydrochloride - Drug Profile 112
Cell Therapy for Oncology - Drug Profile 116
pazopanib hydrochloride - Drug Profile 118
LY-2801653 - Drug Profile 123
selinexor - Drug Profile 124
GL-0817 - Drug Profile 127
Poly-ICLC - Drug Profile 128
golvatinib - Drug Profile 130
AT-406 - Drug Profile 132
Antisense Oligonucleotide for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 135
GSK-2636771 - Drug Profile 136
S-488210 - Drug Profile 137
LJM-716 - Drug Profile 138
MGCD-265 - Drug Profile 140
pexastimogene devacirepvec - Drug Profile 142
JX-929 - Drug Profile 144
HF-10 - Drug Profile 145
MGCD-516 - Drug Profile 146
NBTXR-3 - Drug Profile 147
IC-1001 - Drug Profile 149
imgatuzumab - Drug Profile 150
urelumab - Drug Profile 152
trametinib dimethyl sulfoxide + uprosertib - Drug Profile 154
LY-2606368 - Drug Profile 156
MV-NIS - Drug Profile 157
LGK-974 - Drug Profile 159
INC-280 - Drug Profile 160
GC-4419 - Drug Profile 162
HSV-1716 - Drug Profile 163
interleukin-15 - Drug Profile 165
MTL-005 - Drug Profile 166
IMGN-289 - Drug Profile 168
Cell Therapy to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 169
Gene Therapy to Activate p53 for Oncology - Drug Profile 170
GSK-2849330 - Drug Profile 171
GX-051 - Drug Profile 172
DTP-348 - Drug Profile 173
MEDI-6383 - Drug Profile 175
cetuximab biosimilar - Drug Profile 176
Monoclonal Antibody to Target CD147 for Pancreatic Cancer and Head and Neck Cancer Squamous Cell Carcinoma - Drug Profile 177
cetuximab biosimilar - Drug Profile 179
Small Molecules to Inhibit 30S RNA for Head And Neck Cancer Squamous Cell Carcinoma and Oral Cancer - Drug Profile 180
Antibody to Inhibit FRMD4A for Oncology - Drug Profile 181
Monoclonal Antibody for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 182
cetuximab biosimilar - Drug Profile 183
cetuximab biosimilar - Drug Profile 184
KGP-94 - Drug Profile 185
Monoclonal Antibodies to Antagonize Frizzled Receptors for Breast Cancer and Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 186
RNAi Oligonucleotide to Inhibit Casein Kinase 2 for Cancer - Drug Profile 187
Gene Therapy to Activate p53 for Head and Neck Squamous Cell Carcinoma - Drug Profile 189
SHetA-2 - Drug Profile 190
SGI-7079 - Drug Profile 191
Small Molecules to Inhibit CREB Protein for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile 192
Small Molecules for Head and Neck Cancer - Drug Profile 193
Head And Neck Cancer Squamous Cell Carcinoma - Recent Pipeline Updates 194
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects 243
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products 244
Head And Neck Cancer Squamous Cell Carcinoma - Product Development Milestones 245
Featured News & Press Releases 245
Appendix 254
Methodology 254
Coverage 254
Secondary Research 254
Primary Research 254
Expert Panel Validation 254
Contact Us 255
Disclaimer 255

List of Tables
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2014 14
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 17
Number of Products under Development by Companies, H2 2014 (Contd..1) 18
Number of Products under Development by Companies, H2 2014 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2014 21
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Development, H2 2014 24
Products under Development by Companies, H2 2014 25
Products under Development by Companies, H2 2014 (Contd..1) 26
Products under Development by Companies, H2 2014 (Contd..2) 27
Products under Investigation by Universities/Institutes, H2 2014 28
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2014 29
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 30
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 31
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Shionogi & Co., Ltd., H2 2014 32
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Amgen Inc., H2 2014 33
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2014 34
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by GlaxoSmithKline plc, H2 2014 35
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Celltrion, Inc., H2 2014 36
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Novartis AG, H2 2014 37
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2014 38
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by ImmunoGen, Inc., H2 2014 39
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Santaris Pharma A/S, H2 2014 40
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by CEL-SCI Corporation, H2 2014 41
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by OXiGENE, Inc., H2 2014 42
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Takara Bio Inc., H2 2014 43
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2014 44
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by PCI Biotech AS, H2 2014 45
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Nanobiotix, H2 2014 46
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2014 47
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Virttu Biologics Limited, H2 2014 48
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Ascenta Therapeutics, Inc., H2 2014 49
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Onconova Therapeutics, Inc., H2 2014 50
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Genexine, Inc., H2 2014 51
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Viventia Biotechnologies Inc., H2 2014 52
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Oncovir, Inc., H2 2014 53
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Gliknik, Inc., H2 2014 54
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2014 55
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Agonox, H2 2014 56
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Tolero Pharmaceuticals, Inc., H2 2014 57
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by AlphaMab Co., Ltd, H2 2014 58
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by SillaJen Co. Ltd., H2 2014 59
Head And Neck Cancer Squamous Cell Carcinoma - Pipeline by Mirati Therapeutics Inc., H2 2014 60
Assessment by Monotherapy Products, H2 2014 61
Assessment by Combination Products, H2 2014 62
Number of Products by Stage and Target, H2 2014 65
Number of Products by Stage and Mechanism of Action, H2 2014 70
Number of Products by Stage and Route of Administration, H2 2014 74
Number of Products by Stage and Molecule Type, H2 2014 77
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics - Recent Pipeline Updates, H2 2014 198
Head And Neck Cancer Squamous Cell Carcinoma - Dormant Projects, H2 2014 247
Head And Neck Cancer Squamous Cell Carcinoma - Discontinued Products, H2 2014 248

List of Figures
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma, H2 2014 14
Number of Products under Development for Head And Neck Cancer Squamous Cell Carcinoma - Comparative Analysis, H2 2014 15
Number of Products under Development by Companies, H2 2014 16
Number of Products under Investigation by Universities/Institutes, H2 2014 20
Comparative Analysis by Late Stage Development, H2 2014 22
Comparative Analysis by Clinical Stage Development, H2 2014 23
Comparative Analysis by Early Stage Products, H2 2014 24
Assessment by Monotherapy Products, H2 2014 61
Number of Products by Top 10 Target, H2 2014 63
Number of Products by Stage and Top 10 Target, H2 2014 64
Number of Products by Top 10 Mechanism of Action, H2 2014 68
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 69
Number of Products by Top 10 Route of Administration, H2 2014 73
Number of Products by Stage and Top 10 Route of Administration, H2 2014 74
Number of Products by Top 10 Molecule Type, H2 2014 75
Number of Products by Stage and Top 10 Molecule Type, H2 2014 76

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *